Cancer Chemotherapy: an Introduction
- ISBN-10
- 1447116879
- ISBN-13
- 9781447116875
- Series
- Cancer Chemotherapy
- Category
- Medical
- Pages
- 209
- Language
- English
- Published
- 2011-12-21
- Publisher
- Springer
- Author
- Terry J. Priestman
Description
This book is intended as an introduction to the drug treatment of cancer. It is almost ten years since the last edition was written. In the intervening time, there have been numerous developments in cancer chemotherapy and in order to cover these the majority of the text has been completely revised and rewritten. In addition, two new chapters have been introduced, one on the safe handling of cytotoxic drugs and the other on biological response modifiers. In order to incorporate this new information without any undue increase in the length of the text the chapters on a combined approach to treatment have been omitted. This is not because interdisciplinary collaboration is no longer considered important but is a reflection of the fact that, in most centres, it has become the norm in cancer management and its central role in successful treatment no longer needs to be stressed quite so strongly. The four chapters in the last edition which dealt with the team approach to cancer therapy have been replaced by a single chapter on the place of chemotherapy in the overall treatment of cancer. Unfortunately, despite all the innovations of the last decade, it has become increasingly clear that much of the promise offered by drug treatment during the 1960s and 1970s has not been fulfilled.
Get the book
Other editions
Similar books
-
Handbook of Cancer Chemotherapy
By Samir N. Khleif, Roland T. SkeelThe handbook is a practical, diseased-focused pocket reference that emphasizes the best current medical practice as it relates to the delivery of chemotherapeutic drugs.
-
Cancer Chemotherapy
By Edward S. GreenwaldCancer Chemotherapy: Medical Outline Series discusses the benefits and risks of cancer chemotherapy. This book is composed of 11 chapters that cover the pharmacologic and therapeutic potentials of some chemotherapeutic agents.
-
Cancer Chemotherapy in Clinical Practice
By Terrence PriestmanThis excellent new book summarizes the whole range of systemic cancer therapies, explaining their mode of action and potential side-effects, as well as their clinical applications.
-
Oral Complications of Cancer Chemotherapy
By Douglas E. Peterson, Stephen T. SonisThis new work on oral complications of cancer chemotherapy is edited by two dentists who have made pioneering contributions in this previously neglected area.
-
Marijuana As Medicine?: The Science Beyond the Controversy
By Institute of Medicine, Janet Joy, Alison MackThe Science Beyond the Controversy Institute of Medicine, Janet Joy, Alison Mack. become dependent on illicit drugs than are women. The risk of drug dependence for white Americans is approximately double that for African Americans.
-
Nanotechnology Applications for Cancer Chemotherapy
By Sanyog Jain, Kaisar Raza, Ashish Kumar AgrawalIn addition, this book also explores the evolving targeting approaches specific to the cancer site and type.
-
Physicians' Cancer Chemotherapy Drug Manual 2020
By Vincent T. DeVita Jr., Edward ChuWritten by world-class experts in clinical cancer therapeutics, Physicians’ Cancer Chemotherapy Drug Manual 2020 provides a complete, easy-to-use catalog of over 100 drugs and commonly used drug regimens—both on- and off-label—for the ...
-
Cancer Chemotherapy: A Nursing Process Approach
By Margaret Barton-BurkeThis text for beginning and advanced oncology nurses integrates the nursing process, including nursing diagnosis, with the administration of cancer chemotherapeutic agents.
-
Drug Resistance As a Biochemical Target in Cancer Chemotherapy
By Makoto OgawaThis book is divided into four parts encompassing 18 chapters that summarize the results of both preclinical and clinical research on circumvention of drug resistance.
-
The Expanding Role of Folates and Fluoropyrimidines in Cancer Chemotherapy
By Y. RustumAlthough 5-fluorouracil (Fura) is the drug of choice for the treat ment of patients with advanced colorectal cancer, this agent has limited effectiveness with a reported response rate of 10-20% and a duration of response of only 6-9 ...